ATHE
Alterity Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · AU
$2.43
−7.25%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.65
From 52W high−58.74%
Volume21891.00
Market cap$44.25M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.65
From 52W high
−58.74%
Volume
21891.00
Market cap
$44.25M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
P/E (TTM)
—
RSI (14)
24.3
MomentumView details →
1D Return
−7.25%
YTD Return
−16.88%
SummaryUpdated Jun 1, 2026
Alterity Therapeutics Limited (ASX:ATHE) is an Australian biotechnology company founded in 1997 and headquartered in Melbourne. Originally incorporated as Prana Biotechnology Limited, the company rebranded to its current name in April 2019. Alterity focuses on developing therapeutic drugs to treat neurodegenerative diseases, particularly Alzheimer's disease, Huntington's disease, Parkinson's disease, and other neurological disorders. As a clinical-stage biotechnology company, Alterity has been publicly traded since 2003 and represents the emerging field of precision medicine targeting neurodegeneration through novel therapeutic approaches.
Similar companies
Latest newsMore news →
Alterity Therapeutics presented new analyses of ATH434 Phase 2 data in multiple system atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders, reporting that ATH434 50 mg slowed functional decline by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate.15d agoAlterity Therapeutics announced the granting of a new U.S. composition of matter patent for its drug candidate ATH434, extending protection to at least 2045.69d agoAlterity Therapeutics received FDA End-of-Phase 2 meeting minutes confirming the registrational pathway for ATH434 in Multiple System Atrophy.105d ago